

106 OCT 2005
44

PATENT APPLICATION

IN THE U.S. PATENT AND TRADEMARK OFFICE

October 3, 2005

Applicant(s): Hiroshi SHIKU

For: METHOD AND COMPOSITION FOR REGULATING ACTIVITY OF
REGULATORY T CELLS

Serial No.: 10/525 145

Group: Unknown

Confirmation No.: 5607

Filed: February 16, 2005 Examiner: Unknown

International Application No.: PCT/JP2003/011080

International Filing Date: August 29, 2003

Atty. Docket No.: Furuya 1417

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the provisions of Rules 1.97(b)(3) and 1.98, enclosed are copies of publications discussed in the above application.

Favorable consideration is solicited.

Respectfully submitted,


Terryence F. Chapman

TFC/ad

FLYNN, THIEL, BOUTELL & TANIS, P.C. 2026 Rambling Road Kalamazoo, MI 49008-1631 Phone: (269) 381-1156 Fax: (269) 381-5465	Dale H. Thiel David G. Boutell Ronald J. Tanis Terryence F. Chapman Mark L. Maki Liane L. Churney Brian R. Tumm Steven R. Thiel Donald J. Wallace Kevin L. Pontius Sidney B. Williams, Jr.	Reg. No. 24 323 Reg. No. 25 072 Reg. No. 22 724 Reg. No. 32 549 Reg. No. 36 589 Reg. No. 40 694 Reg. No. 36 328 Reg. No. 53 685 Reg. No. 43 977 Reg. No. 37 512 Reg. No. 24 949
--	--	---

Encl: Form PTO-1449

One copy of each cited publication

INFORMATION
DISCLOSURE
CITATION

Applicant: Hiroshi SHIKU

Ser. No.: 525 145

Filed: February 16, 2005

Conf. No.: 5607

Atty. Docket No.: Furuya 1417

Group: Unknown

Date: October 3, 2005

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	(Include Author, Title, Date, Pages, Etc.)
	AA	<i>Intradermal Immunization of C3H Mice against a Sarcoma That Originated in an Animal of the Same Line</i> , Ludwik Gross, M.D., Cancer Research, 3:326-333 (1943) 8 pages
	AB	<i>ANTIGENIC PROPERTIES OF CHEMICALLY INDUCED TUMORS</i> , Lloyd J. Old, et al., Annals New York Academy of Sciences, 101:80-106 (1962) 27 pages
	AC	<i>The Murine Antitumor Immune Response and Its Therapeutic Manipulation</i> , Robert J. North, Advances in Immunology 35:89-155 (1984) 34 pages
	AD	<i>Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells</i> , Philip D. Greenberg, 49:281-355 (1991) 74 pages
	AE	<i>The role of CD4+T cell responses in antitumor immunity</i> , Drew M. Pardoll, et al., Current Opinion in Immunology, 10:588-594 (1998) 7 pages
	AF	<i>Differential Tumor Surveillance by Natural Killer (NK) and NKT Cells</i> , Mark J. Smyth, et al., J. Exp. Med., 191:661-668 8 pages
	AG	<i>NKT cells and tumor immunity - a double-edged sword</i> , Mark J. Smyth, et al., Nature Immunology, 1:459-460 (2000) 2 pages
	AH	<i>NKT cells - conductors of tumor immunity?</i> , Mark J. Smyth, et al., Current Opinion in Immunology, 14:165-171 (2002) 7 pages
	AI	<i>Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα 14 NKT cells</i> , Tetsu Kawano, et al., Proc. National Academy of Sciences, 95:5690-5693 (1998) 4 pages
	AJ	<i>The central Role of CD4+ T Cells in the Antitumor Immune Response</i> , Kenneth Hung, et al., J. Exp. Med., 188:2357-2368 (1998) 12 pages
	AK	<i>Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors</i> , Ferry Ossendorp, et al., 187:693-702 (1998) 9 pages
	AL	<i>The role of MHC class II-restricted tumor antigens and CD4+T cells in antitumor immunity</i> , Rong-Fu Wang, Trends in Immunology, 5:269-276 (2001) 8 pages
	AM	<i>Regulatory T Cells in Autoimmunity</i> , Ethan M. Shevach, Annu. Rev. Immunol. 18:423-449 (2000) 27 pages
	AN	<i>The role of different subsets of T regulatory cells in controlling autoimmunity</i> , Maria-Grazia Roncarolo, et al., Current Opinion in Immunology, 12:676-683 (2000) 8 pages
EXAMINER SIGNATURE		DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION
DISCLOSURE
CITATION

Applicant: Hiroshi SHIKU

Ser. No.: 10/525 145

Filed: February 16, 2005

Conf. No.: 5607

Atty. Docket No.: Furuya 1417

Group: Unknown

Date: October 3, 2005

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	(Include Author, Title, Date, Pages, Etc.)
	AA	<i>Induction of Tumor Immunity by Removing CD25⁺ CD4⁺ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity</i> , Jun Shimizu, et al., The American Association of Immunologists, 163:5211-5218 (1999) 8 pages
	AB	<i>Immunologic tolerance maintained by CD25⁺CD4⁺ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance</i> , Shimon Sakaguchi, et al., Immunological Reviews, 182:18-32 (2001) 15 pages
	AC	<i>Policing the regulators</i> , Shimon Sakaguchi, Nature Immunology, 2:283-284 (2001) 2 pages
	AD	<i>Regulatory T cells in the control of immune pathology</i> , Kevin J. Maloy, et al., Nature Immunology, 2:816-822 (2001) 4 pages
	AE	<i>CD4⁺CD25⁺ SUPPRESSOR T CELLS: MORE QUESTIONS THAN ANSWERS</i> , Ethan M. Shevach, Nature Reviews Immunology, 2:389-400 (2002) 12 pages
	AF	<i>A conditioned dendritic cell can be a temporal bridge between a CD4⁺ T-helper and a T-killer cell</i> , John Paul Ridge, et al., Nature, 393:474-478 (1998) 5 pages
	AG	<i>Help for cytotoxic-T-cell responses is mediated by CD40 signalling</i> , Sally R.M. Bennett, et al., Nature 393:478-480 (1998) 3 pages
	AH	<i>T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions</i> , Stephen P. Schoenberger, et al., Nature, 393:480-483 (1998) 4 pages
	AI	<i>CD40-independent Pathways of T Cell Help for Priming of CD8⁺ Cytotoxic T Lymphocytes</i> , Zhengbin Lu, et al., J. Exp. Med., 191:541-550 (2000) 10 pages
	AJ	<i>Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity</i> , Hiroyoshi Nishikawa, et al., Proc. National Academy of Sciences, 98: 14571-14576 (2001) 6 pages
	AK	<i>Immunologic Self-Tolerance Maintained by CD25⁺CD4⁺ Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte-associated Antigen 4</i> , Takeshi Takahashi, et al., J. Exp. Med. 192:303-309 (2000) 7 pages
	AL	<i>Cytotoxic T Lymphocyte-associated Antigen 4 Plays an Essential Role in the Function of CD25⁺CD4⁺ Regulatory Cells that Control Intestinal Inflammation</i> , Simon Read, et al., J. Exp. Med. 192:295-302 (2000) 8 pages
	AM	<i>Stimulation of CD25⁺CD4⁺ regulatory T cells through GITR breaks immunological self-tolerance</i> , Jun Shimizu, et al., Nature Immunology 3:135-142 (2002) 8 pages
	AN	
EXAMINER SIGNATURE		DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION
DISCLOSURE
CITATION

Applicant: Hiroshi SHIKU
 Ser. No.: 11/525 145 Filed: February 16, 2005
 Conf. No.: 5607 Atty. Docket No.: Furuya 1417
 Group: Unknown
 Date: October 3, 2005

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	(Include Author, Title, Date, Pages, Etc.)
	AA	<i>HEDJ, an Hsp40 Co-chaperone Localized to the Endoplasmic Reticulum of Human Cells, Min Yu, et al., Journal of Biological Chemistry, 275 (32): 24984-24992 (2000) 9 pages</i>
	AB	<i>Human DNA Ligase I cDNA: Cloning and functional expression in <i>Saccharomyces cerevisiae</i>, Proc. National Academy of Sciences, 87(17): 6679-6683 (1990) 5 pages</i>
	AC	
	AD	
	AE	
	AF	
	AG	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Country Code - Document Number - Kind Code	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Trans.
	AH	WO 03/000894 A1	01-03-2003		(includes English language abstract)
	AI				
	AJ				
	AK				
	AL				
	AM				
	AN				
	AO				
	AP				
	AQ				
	AR				

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.